DelveInsight Estimates a Promising Picture of Graft vs. Host Disease Pipeline Space Landscape as Key 60+ Pharma Companies Working in the Space
November 09, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- DelveInsight Estimates a Promising Picture of Graft vs. Host Disease Pipeline Space Landscape as Key 60+ Pharma Companies Working in the Space The...
The graft versus host disease market to grow at a CAGR of 7.44% during 2021-2027
May 18, 2022 04:00 ET
|
ReportLinker
New York, May 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Graft Versus Host Disease (GvHD) Treatment Market Forecast – Epidemiology & Pipeline Analysis...
Regulatory T-Cell Therapies Market, 2035
January 11, 2022 04:58 ET
|
Research and Markets
Dublin, Jan. 11, 2022 (GLOBE NEWSWIRE) -- The "Regulatory T-Cell Therapies Market by Target Indications, Key Players and Key Geographies: Industry Trends and Global Forecast, 2021-2035" report has...
Regulatory T-Cell Therapies Market by Target Indications, Key Players and Key Geographies : Industry Trends and Global Forecast, 2021-2035
December 10, 2021 03:56 ET
|
ReportLinker
New York, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regulatory T-Cell Therapies Market by Target Indications, Key Players and Key Geographies : Industry...
REGiMMUNE Phase 2a Results of RGI-2001, an Activator of Invariant Natural Killer T Cells, Published in "Biology of Blood and Marrow Transplantation"
March 09, 2017 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Mar 9, 2017) - REGiMMUNE Corporation (RGI) is pleased to announce the publication of its Phase 2a clinical trial results for RGI-2001, a novel liposomal formulation of...
REGiMMUNE Announces Collaboration With JDRF and Pfizer Inc. for Type 1 Diabetes Prevention and Treatment Promoting Regulatory T-Cells
April 14, 2015 13:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Apr 14, 2015) - REGiMMUNE Corporation (RGI) and JDRF today announced a partnership, along with financial assistance and scientific expertise from Pfizer Inc., for a...
REGiMMUNE to Present Its Method for Long-Term Tolerance in Organ Transplantation at World Transplant Congress in San Francisco
July 25, 2014 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Jul 25, 2014) - REGiMMUNE Corporation, a biotechnology company focused on the development of immune regulatory therapeutics with its reVax technology, announced that it...
American Journal of Transplantation Reports REGiMMUNE's Preclinical Results of Its Method for Long-Term Tolerance in Organ Transplantation
February 28, 2014 03:01 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 28, 2014) - REGiMMUNE Corporation announced that the American Journal of Transplantation (AJT) has published its paper that describes a novel approach to long-term...
REGiMMUNE Completes $9.2 Million Series D Financing
February 14, 2014 08:00 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 14, 2014) - REGiMMUNE Corporation announced the closing of a Series D financing earlier this month. The company raised $9.2 million US in this new round, which was...
REGiMMUNE Begins Enrollment for Phase II Clinical Trial for Graft Versus Host Disease
February 06, 2014 10:15 ET
|
REGiMMUNE
TOKYO, JAPAN--(Marketwired - Feb 6, 2014) - REGiMMUNE Corporation announced today that it has begun a Phase II study of its proprietary compound RGI-2001 for GvHD associated with hematopoietic stem...